risedronate delayed-release / Generic mfg. - LARVOL DELTA

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Apr 2027 ➔ Apr 2028 | Trial primary completion date: Apr 2027 ➔ Apr 2028

Trial completion date • Trial primary completion date • Osteoporosis

Drugs for postmenopausal osteoporosis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Osteoporosis • Rheumatology

Comparison table: Some drugs for postmenopausal osteoporosis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Osteoporosis • Rheumatology

Prophylactic Riserodrenate for Patients With Peripheral Lung Tumors Treated With SBRT (clinicaltrials.gov) - P2 | N=84 | Completed | Sponsor: Wake Forest University Health Sciences | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Oncology • Solid Tumor

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting

Bariatric surgery • Enrollment open • Surgery • Osteoporosis

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Apr 2027 | Trial primary completion date: Dec 2024 ➔ Apr 2027

Bariatric surgery • Enrollment open • Surgery • Trial completion date • Trial primary completion date • Osteoporosis

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - P3 | N=200 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2026 ➔ Dec 2024 | Trial primary completion date: Dec 2026 ➔ Dec 2024

Trial completion date • Trial primary completion date • Osteoporosis

Prophylactic Riserodrenate for Patients With Peripheral Lung Tumors Treated With SBRT (clinicaltrials.gov) - P2 | N=84 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Aug 2023 ➔ Mar 2023 | Trial primary completion date: Aug 2022 ➔ Mar 2022

Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Solid Tumor

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss (clinicaltrials.gov) - P3 | N=200 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Osteoporosis

Prophylactic Riserodrenate for Patients With Peripheral Lung Tumors Treated With SBRT (clinicaltrials.gov) - P2 | N=84 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2024 ➔ Aug 2023 | Trial primary completion date: Aug 2023 ➔ Aug 2022

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Solid Tumor

WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss (clinicaltrials.gov) - P3; N=200; Not yet recruiting; Sponsor: Wake Forest University Health Sciences

New P3 trial • Osteoporosis

Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness-A Concise Literature Review. (PubMed, Foods) - "Food, beverages such as coffee, juices, and mineral water, as well as dietary supplements containing multivalent cations, e.g., calcium, magnesium, aluminium, iron, showed to have a deleterious effect on the bioavailability of all the investigated oral bisphosphonates, specifically alendronate, risedronate, ibandronate, minodronate, and etidronate. For risedronate, a delayed-release (DR) tablet was designed to solve the malabsorption problem in the presence of food, hence DR risedronate can be ingested following breakfast. For other oral bisphosphonates, the proper interval between drug and food, beverages, and dietary supplements intake should be maintained to minimize the risk of interactions. The effect of food on pharmacokinetic parameters of selective estrogen receptor modulators (SERMs) was found to be clinically irrelevant."

Journal • Review • Osteoporosis • Rheumatology

History of risedronate. (PubMed, Bone) - "which never actively promoted the drug. Generic forms of risedronate were introduced into the United States in 2015 but are rarely used, although several generic forms are actively marketed in other countries."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis